Centre de Recherche Vaccinale et Biomédicale, Institut Pasteur, 75724 Paris Cedex 15, France.
SourceVaccine 2008 Feb 13; 26(7)
Twenty-eight adults received between 10(2) and 10(8)colony forming units of live Shigella dysenteriae type-1 vaccine SC599, attenuated by deletion of invasion (icsA), iron chelation (ent, fep) and shiga toxin A-subunit (stxA) genes, followed by ciprofloxacin on day 4. Dose-independent diarrhea or change in bowel habit was seen in 3 subjects, without dysentery, vaccinaemia or serious adverse events. Hematology and biochemical parameters were unchanged. Doses of 10(5) or greater induced dose-independent SD1 lipopolysaccharide-specific antibody secreting cell (ASC) responses. Geometric mean number of IgA ASCs per 10(6) PBMCs for 10(5), 10(6), 10(7) and 10(8) groups were respectively 41, 8.8, 26 and 8.5. Serum antibody responses were seen in three subjects. SC599 appears immunogenic with maximum tolerated dose greater than 10(8)CFU.
MeshAdministration, OralAdultAntibodies, BacterialBacterial ProteinsDNA-Binding ProteinsDysentery, BacillaryEnterobactinFemaleGene DeletionHumansMaleProtein SubunitsShiga ToxinShigella VaccinesShigella dysenteriaeTranscription FactorsTreatment OutcomeVaccines, Attenuated
Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't